Understanding how BRAF gene mutations are diagnosed is essential for anyone dealing with potential cancer concerns, as this genetic change plays a crucial role in determining the most effective treatment path.

Introduction: Who Should Undergo BRAF Diagnostics

BRAF gene mutation testing is particularly important for people who have been diagnosed with certain types of cancer or are suspected of having them. The BRAF gene provides instructions for making a protein that helps transmit chemical signals from outside the cell to the cell’s nucleus, and when this gene mutates, it can cause cells to grow and divide uncontrollably, leading to cancer.^[1]

Not everyone needs BRAF testing. This diagnostic test is most commonly recommended for patients with specific cancer types where BRAF mutations are known to occur frequently. These include melanoma, colorectal cancer, non-small cell lung cancer, and certain thyroid cancers. For colorectal cancer, all patients with stage IV or metastatic disease should have BRAF biomarker testing performed.^[3] In melanoma cases, approximately 50% of all tumors harbor an activating BRAF mutation, making testing particularly valuable for treatment planning.^[16]

For lung cancer patients, BRAF mutations are found in about 3% to 5% of all non-small cell lung cancers, appearing almost exclusively in the adenocarcinoma subtype.^[10] Because this mutation is relatively rare but treatable with targeted therapies, doctors typically recommend testing when lung cancer is diagnosed to ensure patients don’t miss out on potentially beneficial treatments.

The timing of BRAF testing is crucial. Most often, it happens soon after a cancer diagnosis is confirmed through biopsy. Knowing your BRAF status early in your cancer journey can be life-changing because it opens doors to specific targeted treatments that might work better than standard therapies.^[12] For patients with advanced disease that has spread to other parts of the body, BRAF testing becomes even more important as it directly influences which treatment combinations doctors will recommend.

Classic Diagnostic Methods for BRAF Mutations

The primary method for testing BRAF mutation status involves using a biopsy sample of cancer cells. A biopsy is a procedure where a small piece of tissue is removed from your body for examination in a laboratory. This sample can come from the primary tumor where the cancer started or from metastases, which are cancer growths that have spread to other parts of the body such as lymph nodes, liver, or other organs.^[3]

Once the tissue sample is collected, laboratory technicians treat the cancer cells to isolate the tumor’s DNA, which is the genetic material that contains all the instructions for how cells function. This DNA is then carefully studied to look for specific changes or mutations in the BRAF gene. The most common mutation found in cancer is called V600E, where a specific building block in the gene (the amino acid valine at position 600) is replaced with a different one (glutamic acid).^[1]

In colorectal cancer, BRAF mutations are present in approximately 10% to 15% of cases, and the majority of these are V600E mutations.^[3] For melanoma, about 35% of tumors have BRAF mutations, while in thyroid papillary carcinomas, more than 50% show this genetic change.^[3] Understanding these percentages helps doctors know when testing is most likely to provide useful information.

Another testing approach is called a liquid biopsy, which is a newer and less invasive method. Instead of removing tissue from a tumor, doctors take a blood sample and examine what’s called circulating tumor DNA or ctDNA. This is genetic material from cancer cells that has been released into the bloodstream. By analyzing this DNA, laboratories can detect BRAF mutations without needing to perform a surgical biopsy.^[3] Liquid biopsies are particularly useful when tumor tissue is difficult to access or when monitoring how cancer responds to treatment over time.

BRAF testing can be performed as a single-gene test, looking only at the BRAF gene, or as part of a larger panel using next-generation sequencing (NGS). Next-generation sequencing is an advanced technology that can analyze multiple genes simultaneously, providing a comprehensive picture of all the genetic changes present in a tumor. This multi-gene approach is increasingly common because it gives doctors more information about other potential treatment targets beyond just BRAF.^[3]

The test is sometimes called by different names in medical reports, including BRAF mutation analysis or BRAF gene sequencing, but they all refer to the same basic process of identifying whether a BRAF mutation is present.^[3]

Understanding Your Test Results

When you receive your BRAF test results, they will typically be reported in one of two ways. If the result says “BRAF wild-type” or “BRAF WT,” this means no BRAF mutation was found in your cancer. Wild-type is the scientific term for the normal, unchanged version of a gene. If you have wild-type BRAF, your cancer did not develop because of a BRAF mutation, though it may have other genetic changes driving its growth.^[3]

If a mutation is found, the report will specify which type of BRAF mutation you have. The V600E mutation is by far the most common, but other mutations do exist, though they are rare. The specific type of mutation matters because different mutations may respond differently to treatments.^[3]

BRAF serves as both a prognostic factor and a predictive biomarker. As a prognostic factor, it gives information about the usual course of the disease and what outcomes might be expected. As a predictive biomarker, it helps doctors determine which treatments are more or less likely to be effective against your particular cancer.^[3] For example, in colorectal cancer, tumors with BRAF mutations typically do not respond well to certain drugs called EGFR inhibitors, which are often used when BRAF is wild-type.

Location Matters in BRAF Testing

Interestingly, where a tumor develops in the body can affect the likelihood of finding a BRAF mutation. In colorectal cancer, BRAF mutations are more common in right-sided colon cancers (the proximal colon, which is the part closer to where the small intestine connects) compared to left-sided colon cancers (the distal colon) and rectal cancers.^[3] This pattern helps doctors understand when testing might be most informative and what results to expect.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new ways of using existing treatments. Many clinical trials for cancer specifically enroll patients based on their biomarker status, including BRAF mutations. Understanding your BRAF status is therefore not just important for current treatment decisions but also for determining which clinical trials you might be eligible to join.

For patients with metastatic melanoma whose tumors have a BRAF V600 mutation, multiple clinical trials have been conducted to test different treatment approaches. One major trial called DREAMseq compared starting treatment with immunotherapy drugs versus starting with targeted therapy drugs in patients with this specific mutation. The trial found that patients treated first with the immunotherapy combination of ipilimumab and nivolumab had better survival rates than those who started with targeted therapy—72% versus 52% alive at 2 years.^[8] This trial was stopped early because the difference was so significant, and the findings are expected to change how doctors approach treatment for these patients.

In colorectal cancer clinical trials, BRAF mutation status is frequently used as a criterion for enrollment. Studies testing combinations of BRAF inhibitors with other drugs specifically recruit patients with BRAF-mutated tumors because these are the only patients who could potentially benefit from BRAF-targeted therapies.^[9] Without documented BRAF mutation status, patients cannot participate in these important research studies that might offer access to promising new treatments.

For lung cancer, clinical trials testing BRAF-targeted therapies in non-small cell lung cancer also require confirmation of BRAF mutation status as part of the enrollment criteria. Given that BRAF mutations occur in only about 3% to 5% of lung cancer cases, finding and enrolling eligible patients for these trials depends entirely on widespread testing.^[10]

The testing methods used for clinical trial qualification are typically the same as those used for standard diagnosis—tissue biopsy with genetic analysis or liquid biopsy. However, clinical trials may have specific requirements about when the testing was performed, which laboratory conducted the test, or which testing method was used. Some trials accept historical test results from when you were first diagnosed, while others require fresh testing to ensure the most current information.

The Importance of Comprehensive Testing

Many modern clinical trials don’t just look at BRAF status alone but consider multiple biomarkers together. This is why next-generation sequencing panels that test many genes at once are becoming more common. These comprehensive tests can reveal not just BRAF status but also other mutations that might make you eligible for different trials or treatments.^[3]

The classification of BRAF mutations is also important for clinical trials. Scientists now divide BRAF mutations into three different classes based on their biological characteristics. Class I includes the V600 mutations, which are the most common. Classes II and III include non-V600 mutations, which may behave differently and respond to different treatments.^[2] Clinical trials are increasingly designed to target specific classes of BRAF mutations, so knowing exactly which type you have can open up additional options.

Patient Experiences with BRAF Testing

Real patient stories highlight how BRAF testing can change the course of cancer treatment. One melanoma patient described learning about her BRAF-positive status as “my first ray of hope” because it meant she had access to targeted treatments specifically designed for her type of cancer.^[13] Another patient emphasized gratitude to the scientists who discovered tests to identify BRAF mutations and developed targeted medications to treat them, noting that knowing her BRAF status helped her find the best course of treatment.^[12]

These stories underscore an important point: BRAF testing isn’t just about gathering medical data—it’s about giving patients and their doctors the information they need to make the most informed decisions possible about treatment. The knowledge that comes from a simple genetic test can mean the difference between receiving treatments that may or may not work and accessing therapies specifically designed to target the molecular changes driving your cancer.